Product Details
Synonyms
CTSB, CPSB, APPS
Source
Human Cathepsin B (L26V) Protein, Tag Free (CTB-H5213) is expressed from human 293 cells (HEK293). It contains AA Arg 18 - Ile 339 (Accession # P07858-1 (L26V)).
Predicted N-terminus: Arg 18
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries no "tag".
The protein has a calculated MW of 35.9 kDa. The protein migrates as 30-33 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).
Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Supplied as 0.2 μm filtered solution in 20 mM NaAC, 0.2 M NaCl, pH4.8 with glycerol as protectant.
Contact us for customized product form or formulation.
Shipping
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Storage
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Human Cathepsin B (L26V) Protein, Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS

The purity of Human Cathepsin B (L26V) Protein, Tag Free (Cat. No. CTB-H5213) is more than 90% and the molecular weight of this protein is around 35-50 kDa verified by SEC-MALS.
Report
Bioactivity
Measured by its ability to cleave the fluorogenic peptide substrate Z-LR-AMC. The specific activity is >2,000 pmol/min/μg (QC tested).
Protocol
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
Cathepsin B
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
2 Details
- Highest Development Stage:
Phase 2 Clinical
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521



















